In consideration of the clinical implications of our results, the suppression of the oncogenic MAPK pathway by BRAF or MEK inhibitors may be a useful molecular targeted drug for cancer metastasis in BRAFV600E/PTEN loss melanoma. This evidence concerns the gene PTEN and melanoma.